This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
What's in the Cards for Sunesis (SNSS) This Earnings Season?
by Zacks Equity Research
Sunesis Pharmaceuticals' (SNSS) operating expenses are expected to be higher in the first quarter due to clinical studies on its lead pipeline candidate, vecabrutinib.
3 Tech Stocks for Growth Investors to Buy Right Now
by Benjamin Rains
Let's check out three tech stocks that came through our screen today that growth investors might want to consider at the moment...
Alkermes (ALKS) Reports Narrower-Than-Expected Loss in Q1
by Zacks Equity Research
Alkermes (ALKS) reports narrower-than-expected loss and sales beat in the first quarter of 2019.
Biogen (BIIB) Beats on Q1 Earnings, Spinraza Drives Sales
by Zacks Equity Research
Biogen (BIIB) beats estimates for both earnings and sales in the first quarter fueled mainly by strong performance of its muscle disease drug, Spinraza in international markets.
Biogen (BIIB) Q1 Earnings & Sales Beat Estimates
by Zacks Equity Research
Biogen (BIIB) beat estimates for both earnings and sales in the first quarter fueled mainly by strong performance of its muscle disease drug, Spinraza in international markets.
What's in Store for Celgene Corporation (CELG) Q1 Earnings?
by Zacks Equity Research
Investors are looking forward to Revlimid's performance and updates on the impending acquisition agreement with Bristol-Myers, when Celgene Corporation (CELG) reports Q1 results.
Biogen (BIIB) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
While sales of Biogen's (BIIB) MS franchise are expected to decline in the first quarter of 2019 that of Spinraza are likely to increase.
Will Bristol-Myers (BMY) Disappoint This Earnings Season?
by Zacks Equity Research
Performance of Opdivo and the impending acquisition of Celgene Corporation will be key areas of focus for the investors, when Bristol-Myers (BMY) reports first-quarter results.
Roche's (RHHBY) Q1 Sales Strong on Solid Demand for New Drugs
by Zacks Equity Research
Roche's (RHHBY) performance in the first quarter of 2019 is driven by solid strength of new drugs, which more than offset competition from biosimilars.
Biogen (BIIB) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Biogen (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biogen (BIIB) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Biogen (BIIB) closed at $232.37 in the latest trading session, marking a -0.91% move from the prior day.
Biogen (BIIB) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Biogen (BIIB) closed the most recent trading day at $237.58, moving -0.9% from the previous trading session.
Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Biogen (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Celgene Gets Positive CHMP Nod for Revlimid Label Expansion
by Zacks Equity Research
Celgene (CELG) receives positive CHMP opinion for label expansions of IMiD medications - Revlimid and Imnovid.
Merck KgaA's (MKGAF) MS Drug Mavenclad Gets FDA Approval
by Zacks Equity Research
Merck KaaA (MKGAF) announces approval of Mavenclad in the United States as a treatment for multiple sclerosis. The drug is already approved in other countries including Europe.
4 Small Biotech Stocks Likely to Witness More Upside in 2019
by Zacks Equity Research
The biotech space is witnessing a rally so far in 2019. Here we discuss four stocks that are likely to witness a continuation of the uptrend going ahead.
Novartis (NVS) Receives FDA Approval for MS Drug Mayzent
by Zacks Equity Research
Novartis (NVS) obtains FDA approval for Mayzent for the treatment of relapsing forms of MS.
Biotech Stock Roundup: BIIB & CNAT Crash on Study Failures, LXRX Gets CRL
by Zacks Equity Research
Key highlights of the past week are multiple study failures and other pipeline updates.
Celgene (CELG) Submits NDA for MS Drug to FDA for Review
by Zacks Equity Research
Celgene (CELG) progresses with the development of its MS candidate, as it submits an application for the same to the FDA.
AbbVie's Psoriasis Drug Skyrizi Gets First Approval in Japan
by Zacks Equity Research
AbbVie's (ABBV) psoriasis drug Skyrizi gains the maiden approval in Japan for treating adults with plaque psoriasis, generalized pustular psoriasis, erythrodermic psoriasis and psoriatic arthritis.
Biogen Stock Crashes on Termination of Alzheimer's Studies
by Zacks Equity Research
Biogen (BIIB) and its Japanese partner, Eisai discontinue two late-stage studies evaluating aducanumab, in patients with Alzheimer's disease.
Company News For Mar 22, 2019
by Zacks Equity Research
Companies in the news are: BIIB, CAG, DRI, WSM
Jobless Claims Dip, Philly Fed Swings, Biogen (BIIB) Plummets
by Mark Vickery
Jobless claims fell back to within the long-term range to 221K, Philly Fed surprised at 13.7 (after a negative February) and Biogen's phase 3 trial is halted.
Initial Jobless Claims Decline
by Zacks Equity Research
Initial Jobless Claims Decline
Jobless Claims Dip, Philly Fed Swings, Biogen (BIIB) Plummets
by Mark Vickery
Jobless claims fell back to within the long-term range to 221K, Philly Fed surprised at 13.7 (after a negative February) and Biogen's phase 3 trial is halted.